First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial

First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial
The first ovarian cancer patient in the APOLLO Phase 1 clinical trial has been dosed with FATE-NK100, Fate Therapeutics‘ investigational NK (natural killer) cell therapy. The Phase 1 trial (NCT03213964), which is currently recruiting participants, was designed to determine the maximum dose of a single FATE-NK100 infusion — the primary endpoint — in women with recurrent

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *